A Phase 2/3 interventional study of ABX464 and Placebo in Crohn Disease, sponsored by Abivax S.A.. Withdrawn at 1 site in Belgium. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-31.
Sponsored by Abivax S.A. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.
Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 174th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2022, is one of 5 in phase 2/3, and was the 124th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Belgium, United States, Argentina and 27 more countries
Ages 18+
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Belgium, United States, Brazil and 7 more countries
Ages 18–80
Imelda GI Clinical Research Center · Sites in Belgium
Ages 16+
Janssen Research & Development, LLC · Sites in Belgium, United States, Austria and 14 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 58 · Phase 3 94 · Phase 4 9
First in 2001; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 211 across the 175 interventional studies, 257 across the 19 observational. Of the 135 that completed or were terminated, 83 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 194 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 2 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Crohn Disease with a site in Belgium that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 15 to your calendar (.ics) → With an account.
Among the 194 studies in Crohn Disease with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464, administered once daily (QD), in inducing clinical remission and endoscopic response in patients with moderate to severe active Crohn's disease (CD) who have inadequate response, loss of response, or intolerance to prior corticosteroid and/or immunosuppressant treatment and/or biologics. This study consists of a 28 day Screening Period, a 52 week Treatment Period; including a 12 week double blinded (Cohort 1) or open label (Cohort 2) Induction Phase and a 40 week double blinded (responders) or open label (nonresponders) Maintenance Phase; and a 4 week Follow up Period, which will consist of an End of Study (EOS) visit
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464, administered once daily (QD), in inducing clinical remission and endoscopic response in patients with moderate to severe active Crohn's disease (CD) who have inadequate response, loss of response, or intolerance to prior corticosteroid and/or immunosuppressant treatment and/or biologics. This study consists of a 28 day Screening Period, a 52 week Treatment Period; including a 12 week double blinded (Cohort 1) or open label (Cohort 2) Induction Phase and a 40 week double blinded (responders) or open label (nonresponders) Maintenance Phase; and a 4 week Follow up Period, which will consist of an End of Study (EOS) visit
Patient eligibility will be determined during a 4 week (28 days) Screening Period. Entry criteria will be based on confirmation of active moderate to severe ileal, ileocolic, or colonic CD. Approximately 930 patients will participate in this study (ABX464 Dose A N = 380, ABX464 Dose B N = 380, placebo N = 170).
On Day 0, eligible patients will be randomized into 2 cohorts:
Cohort 1: Double blinded Induction Phase according to a 1:1:1 ratio into 3 treatment groups as follows:
Cohort 2: Open-label Induction Phase according to a 1:1 ratio into 2 treatment groups as follows:
At the end of the 12-week Induction Phase, all patients will be evaluated for the co-primary endpoints, namely induction of clinical remission and endoscopic improvement in addition to the secondary and exploratory endpoints. All patients will also be evaluated for treatment response. The determination of whether patients will be considered treatment responders versus nonresponders, responders being defined as patients with a reduction from baseline in Crohn's Disease Activity Index (CDAI) of ≥ 70 points.
Patients will be allocated to the different maintenance treatment regimens according to the following rules:
At Week 24, nonresponders who received open label ABX464 Dose A QD in the Maintenance Phase will be assessed for treatment response. If patients have not achieved treatment response at Week 24, patients should discontinue study drug. All patients, including those who have had treatment response in Week 12, can be discontinued due to disease worsening.
Patients will also be evaluated for safety and efficacy throughout the Induction and Maintenance Phases. From Day 0 onwards, all eligible patients will be followed at the investigational site on Week 1, Week 2, Week 4, Week 8, Week 12, and every 4 weeks until Week 52. Ileocolonoscopy will be performed in accordance with the Schedule of Activities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose A QD
Drug: ABX464
Dose B QD
Drug: ABX464
Matching dose
Drug: Placebo
ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.
In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.
The co-primary objectives of the study are to determine the efficacy of ABX464 in inducing clinical remission and endoscopic improvement after 12 weeks of study treatment in patients with moderate to severe active CD who have inadequate response, loss of
Percentage of patients in clinical remission at Week 12, defined as CDAI of ≤ 150
Time frame: from baseline, at Week 12
Co-primary objectives of the study are to determine the efficacy of ABX464 in inducing clinical remission and endoscopic improvement after 12 weeks of study treatment in patients with moderate to severe active CD who have inadequate response, loss of
Percentage of patients with endoscopic improvement at Week 12, defined as a decrease from baseline of ≥ 50% in the global SES-CD (SES CD 50)
Time frame: from baseline, at Week 12
To evaluate the safety of ABX464
* Number and rate of all adverse events, causally related adverse events, all Serious Adverse Events (SAEs), and causally-related SAEs classified by severity * Incidence of treatment-emergent SAEs * Incidence of adverse events leading to investigational medicinal product discontinuation * The number of clinically-significant laboratory abnormalities
Time frame: from baseline, at week 12
To evaluate the effect of ABX464 as measured by Patient-Reported-Outcome-based remission (PRO) at Week 12
Number and rates of patients with the following: PRO-based remission at Week 12, defined as abdominal pain ≤ 1 and liquid/soft Stool Frequence (SF) score of ≤ 3, averaged over the 7 days prior to visit
Time frame: from baseline, at week 12
To evaluate the effect of ABX464 on C reactive protein (CRP) and fecal calprotectin levels
Change from Week 0 to Week 12 in CRP and fecal calprotectin levels
Time frame: from baseline, at week 12
To evaluate the effect of ABX464 on patients' quality of life
The scores and changes from Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ)
Time frame: from baseline to week 12
To evaluate the effect of ABX464 on micro RNA (miR) 124 expression in whole blood and in tissue
Change from Week 0 to Week 12 in microRNA-124 levels in total blood (PAXgene®) and in tissue (RNA later)
Time frame: from baseline to week 12
To assess the pharmacokinetics of ABX464 and ABX464-N-Glu
Serum concentration of ABX464 and its main metabolite ABX464-N-Glu levels
Time frame: from baseline, at week 12
To evaluate the effect of ABX464 as measured by endoscopic remission at Week 12
Number and rates of patients with the following: Endoscopic remission at Week 12 defined as SES CD ≤ 4 with at least a 2 point reduction from baseline
Time frame: from baseline, at week 12
To evaluate the effect of ABX464 as measured by clinical response at Week 12
Number and rates of patients with the following: Clinical response at Week 12, defined as a reduction from baseline in CDAI of ≥ 100 points
Time frame: from baseline, at week 12
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2022; primary completion for Sep 2022, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464